Navigation Links
Neurocrine Biosciences Reports First Quarter 2012 Results
Date:5/2/2012

is study assessed once-daily NBI-98854 (12.5mg or 50mg) over a two-week dosing period in 37 randomized subjects. Based on the positive outcome of this study the Company is planning to launch a large Phase IIb trial in mid-2012. This placebo controlled, double-blind, parallel design, multiple dose, twelve week study will assess six-week dosing of NBI-98854, against placebo, followed by six weeks of active treatment with NBI-98854. The study will incorporate a capsule formulation of NBI-98854.

In January of 2012, the Company was notified that the FDA Division of Psychiatry Products had granted Fast Track status to NBI-98854 for neuroleptic-induced tardive dyskinesia. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious diseases and address unmet medical needs.

Urocortin 2 Update
The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with the Company, is conducting a Phase II study of urocortin 2 in acute decompensated heart failure patients. This study is now complete and top-line results are expected shortly.

The Company has completed several Phase I studies and two Phase II studies of urocortin 2 in patients with stable congestive heart failure. These Phase II studies showed urocortin 2 to be well tolerated with positive hemodynamic effects as evidenced by increases in cardiac output and efficiency.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 800-894-5910 (US) or 785-424-1052 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com<
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy ... new comic series designed to educate children about the most ... The Medikidz Explain Epilepsy comic series tells a ... is navigating middle school while living with epilepsy. ... Canadians, there is still so much misinformation and lack of ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... Oncology Group -, BRISBANE, Calif., May 28 ... its clinical trials program through the,initiation of an ... candidate,BSI-201. The trial will assess BSI-201, the first ... portfolio, for the treatment,of uterine carcinosarcoma or malignant ...
... FDA Approval Based on Updated Results Showing a 20% Reduction ... a 22% Improvement of Disease Free Survival at ... III Colon Cancer, Post Surgery -, BRIDGEWATER, N.J., May ... Drug Administration (FDA) approved,the supplemental new drug application (sNDA) to ...
Cached Medicine Technology:BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer 2New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 2New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 3New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data 4
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
(Date:8/22/2014)... again attained the distinguished Magnet hospital designation by ... Program. Considered the gold standard for nursing excellence, ... and professionalism. It is the top international credential ... redesignate Newport Hospital was based on the hospital,s ... practice. , "It is a privilege for us ...
(Date:8/22/2014)... who use reduced-nicotine cigarettes don,t smoke more to make ... a new study. This means they don,t inhale ... The month-long study included 72 adult smokers, aged ... emission levels of 1.2 milligrams (mg) each for one ... the next three weeks. In each of those ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Inner city children have a higher-than-normal ... Researchers followed 516 inner city children in four U.S. cities ... birth until age 5 and found that at least 10 ... peanuts. Because only the three most common types of ... of inner city youngsters with food allergies may be even ...
(Date:8/22/2014)... A new, online conference is coming August 25th-29th, ... no-cost and open to everyone. Over 20 top experts ... advice on how to stop emotional eating, start eating healthier ... eating is not a diet. The concept is about how ... "eat this, don't eat that" approach. , You can sign ...
Breaking Medicine News(10 mins):Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Low-Nicotine Cigarettes May Not Lead to More Smoking 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2
... For the first time, families of murder victims have joined ... executed to speak out against the death penalty. , ... at a special session on the first day of the ... calls the death penalty "inappropriate and unwarranted" for people with ...
... July 6 NeoStem, Inc. (Amex: NBS ... long-term storage of adult stem cells for future medical ... M.D., Ph.D., FACP, FRCP, as the Company,s Vice President ... Among his responsibilities in this position will be overseeing ...
... MINNEAPOLIS, July 6 ATS Medical, Inc. (Nasdaq: ... state-of-the-art cardiac surgery products and services, today announced ... ATS Simulus(R) Semi-Rigid Annuloplasty Band. The Simulus Semi-Rigid ... with Genesee BioMedical and represents the latest addition ...
... ... 20/20 vision after submitting the winning video for a contest sponsored by a prominent ... to a stranger can brighten someone’s day. , ... (Vocus) July 6, 2009 -- In tough times, random acts of kindness ...
... In ... American Orthopaedic Society for Sports Medicine (AOSSM) will present eight research awards and ... ... order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the ...
... acute hunger and undernutrition occurs not in conflicts and ... to an article published this week in open access ... the time of year when the previous year,s harvest ... are scarce, and is often under recognized. Bapu ...
Cached Medicine News:Health News:Death Penalty and Mental Illness: Families of Victims Speak out at National Convention; 'Double Tragedies' Report Released 2Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 2Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 3Health News:NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs 4Health News:ATS Medical Announces FDA Clearance and First Implant of New ATS Simulus Semi-Rigid Annuloplasty Band 2Health News:ATS Medical Announces FDA Clearance and First Implant of New ATS Simulus Semi-Rigid Annuloplasty Band 3Health News:Eye Doctors of Washington Awards DC Resident Free LASIK as Part of its Good Deeds Campaign 2Health News:Eye Doctors of Washington Awards DC Resident Free LASIK as Part of its Good Deeds Campaign 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 2Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 3Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 4Health News:American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting 5
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
McPherson handle. 45 degree angled shafts. Manufactured in titanium....
This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
Medicine Products: